NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NXGL
NEXGEL, Inc.
There isn't enough reported data to score NXGL yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NXGL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NXGL's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NXGL PE Valuation
NXGL has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NXGL Forward outlook
There aren't enough analyst estimates for NXGL to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NXGL on earnings quality, reporting a profit while its opponent remains loss making.
NXGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$14.20 | -$6.20 |
| Q1 2026 | -$8.00 | +$1.00 |
| Q4 2025 | -$7.60 | +$2.40 |
| Q3 2025 | -$7.40 | +$4.20 |
| Q2 2025 | -$8.00 | +$3.40 |
| Q1 2025 | -$9.00 | +$2.00 |
| Q4 2024 | -$10.00 | +$1.20 |
| Q3 2024 | -$11.60 | -$2.00 |
NXGL is still losing money, but far less than before: $14.20 per share over the past year, against $43.20 at its worst in late 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NXGL on profitability, with a higher operating margin.
NXGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.7M | +28% |
| Q1 2026 | $2.7M | -5.6% |
| Q4 2025 | $2.8M | -8.1% |
| Q3 2025 | $2.9M | -0.2% |
| Q2 2025 | $2.9M | +100% |
| Q1 2025 | $2.8M | +122% |
| Q4 2024 | $3M | +181% |
| Q3 2024 | $2.9M | +141% |
NXGL's revenue has held roughly level: $4M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -68% | -46 points |
| Q1 2026 | -36% | -8.5 points |
| Q4 2025 | -43% | -16 points |
| Q3 2025 | -25% | +2.1 points |
| Q2 2025 | -22% | +51 points |
| Q1 2025 | -28% | +41 points |
| Q4 2024 | -28% | +85 points |
| Q3 2024 | -27% | +23 points |
NXGL's operating margin was −68% last quarter, down 46 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NXGL has the stronger cash trend. Its trailing FCF is up 0.1% versus its history, compared with NVO at down 14%.
NXGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $241K | +$1.2M |
| Q3 2025 | -$793K | +$436K |
| Q4 2024 | -$928K | -$256K |
| Q3 2024 | -$1.2M | -$148K |
| Q2 2024 | -$909K | +$473K |
| Q1 2024 | -$1.2M | -$447K |
| Q4 2023 | -$672K | -$15K |
| Q3 2023 | -$1.1M | -$176K |
NXGL has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NXGL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NXGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +40.5K shares |
| 1 year | +18% | +67.9K shares |
| 3 years | +62% | +172K shares |
NXGL has 450,663 diluted shares, up 18% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NXGL Net Leverage
NXGL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NXGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 7.2 | Oversold |
NXGL's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NXGL PE vs Healthcare Sector
NXGL has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over NXGL on trend strength, trading above more of its moving averages.
NXGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.06 | 6.7% below |
| 20 week MA | $6.53 | 42% below |
| 50 week MA | $14.7 | 74% below |
| 100 week MA | $34.7 | 89% below |
| 200 week MA | $39.9 | 90% below |
NXGL is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over NXGL on returns for 2026, with the stronger performance.
NXGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $62.4 | $62.4 | 0% |
| 2022 | $62.4 | $27.2 | -56% |
| 2023 | $27.2 | $42.6 | +57% |
| 2024 | $42.6 | $94.0 | +121% |
| 2025 | $94.0 | $30.6 | -67% |
| 2026 YTD | $30.6 | $3.79 | -88% |
NXGL's yearly returns have swung widely, from +121% in 2024 to −67% in 2025. It's down 88% so far in 2026.